Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation. - Wikidata - awgldk - TriplyDB

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

http://www.wikidata.org/entity/Q42173414

about

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications.Recent updates in utilizing prodrugs in drug delivery (2013-2015).EGFR-targeting peptide-coupled platinum(IV) complexes.Exploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes.Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs.A luminescent ruthenium(II) complex for light-triggered drug release and live cell imaging.Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.Targeting curcumin to specific tumour cell environments: the influence of ancillary ligands.Metal Compounds as Kinase and Phosphatase Inhibitors in Drug Development: The Role of the Metal and Ligands Hypoxia-activated prodrugs and redox-responsive nanocarriers

P2860

Q26774750-38B00AA6-EECB-44C8-8E0B-EC2C2DB091E5 Q37432540-8538CC31-E789-4384-A92A-B23B2D7A6A8C Q38702949-F8346894-2FCB-4290-BD06-CC35B3344103 Q38707872-D6C5B78B-AB40-410E-A1BC-B788FE43C961 Q38712938-C1145A35-5DBA-4F4D-803D-F4E1F9AF592F Q38814550-B577EEC6-DCA9-4291-8EF3-E9F349D2EB44 Q38845855-885DF2B2-D2C0-4B74-9693-47F4FD5BEB99 Q39110234-06161F2D-AA59-42C8-9F19-E3D57680485E Q50863499-1075E137-768F-46F2-A38D-92DA2EA5E15D Q57693525-CF890CE7-6183-4142-B504-16DE9E65D827 Q58694676-E48C0E5A-241A-48B7-9571-EB451C88157A

P2860

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

http://www.wikidata.org/entity/Q42173414

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@en

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@nl

type

label

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@en

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@nl

prefLabel

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@en

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@nl

P1433

Q42173414-A16A45DC-6188-4B38-95F3-1E3CECEF0E93

P1476

Q42173414-46456DC9-456B-4583-B0F7-CE154140A93C

P2093

Q42173414-0E356CAA-0AF6-4C46-BD43-52033DD83598

Q42173414-2FC7EE0E-A291-4661-AD25-3A339C7E90D8

Q42173414-A8FD7F1A-C248-4DFB-8A77-D22C64CAA76B

P2860

Q42173414-0EE54649-34B0-4443-B252-F6E0205155CB

Q42173414-25FD704D-B329-4814-9D37-05DA6A9F0AB2

Q42173414-3587095D-D7F6-484D-915A-1DAFDA808063

Q42173414-3C6F1E53-A56E-400D-B3E5-738E8206EF4F

Q42173414-40F03002-B582-4565-B7D4-39D694643F12

Q42173414-4C291DF2-4643-435F-A128-628B9A802DDC

Q42173414-5D3945EA-75BA-487F-B453-3A56EF888CE8

Q42173414-63B35B9F-3A42-488F-978E-440FFF1D7356

Q42173414-64C5D752-2DE9-4631-9516-32BC3E603B7C

Q42173414-66E229A3-F224-489C-B574-6E165CE78800

P304

Q42173414-F4EA22C6-B07C-4CF7-A22F-8F29E9E568BA

P31

Q42173414-7FC2F4C6-3EE1-4C25-AC7E-A54A0DC2D2DC

P356

Q42173414-AC166B08-1C86-4DAF-BB59-832E09B42DE3

P407

Q42173414-4308DA57-D3F2-486C-8F2B-C99D38A9D550

P433

Q42173414-C7165A17-F153-42BD-8D7E-2C03286BAD8F

P478

Q42173414-0B238571-F15B-4C72-825C-E9C422753286

P50

Q42173414-2F203408-DAED-4924-B05A-29CC629F3680

Q42173414-541172C7-DE7D-4AB0-8C81-DF0C1F36F37C

Q42173414-77852E7F-0448-4157-AC23-BF10316ADA94

Q42173414-96DFE20B-343C-49BD-9FA4-B689E6B6390C

Q42173414-A0CC91BC-DF49-4295-86F7-AC09C0B04919

P577

Q42173414-420C3112-34C8-4D6F-92F7-E136F0393132

P698

Q42173414-4A707648-3E3C-45CF-A020-7428BC742116

P921

Q42173414-F8281700-DF6D-4A3A-B268-891DB34052C1

P932

Q42173414-AB4CE4C6-8F29-43E8-8847-0F3F9E528846

P356

P1433

Angewandte Chemie International Edition

P1476

Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.

@en

P2093

Alexander Roller

http://www.w3.org/2001/XMLSchema#string

Claudia Karnthaler-Benbakka

http://www.w3.org/2001/XMLSchema#string

Diana Groza

http://www.w3.org/2001/XMLSchema#string

P2860

Tyrosine kinase - Role and significance in Cancer.

Skin toxicities associated with epidermal growth factor receptor inhibitors

Exploiting tumour hypoxia in cancer treatment

Epidermal growth factor receptor mutations in lung cancer

Targeting hypoxia in cancer therapy

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

EGFR signaling and drug discovery.

Recent advances in bioreductive drug targeting.

Non platinum metal complexes as anti-cancer drugs.

Cobalt derivatives as promising therapeutic agents

P304

12930-12935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANIE.201403936

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Kushtrim Kryeziu

Christian R Kowol

P577

2014-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25079700

http://www.w3.org/2001/XMLSchema#string

P921

P932

4336855

http://www.w3.org/2001/XMLSchema#string